Skip To Main Content
Atish D. Choudhury on Muck Rack

Atish D. Choudhury

West Newton
As seen in: Color Research & Application, Nature, Medscape, BioRxiv, The Lancet, HemOnc Today, OncLive, European Urology, UroToday, Urology Times and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Atish D.

Contact Atish D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

|
By Atish D. Choudhury, Caiwei Zhong, Wanling Xie
| UroToday Verified
Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer.
Open in Who Shared Issue with article?

VIDEO: ADT break may help therapy responders in metastatic prostate cancer

|
By Erin Theresa Verified, Atish D. Choudhury
| HemOnc Today Verified
VIDEO: ADT break may help therapy responders in metastatic prostate cancer June 16, 2026 2 min watch Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio CHICAGO — In this video, Atish D.
Open in Who Shared Issue with article?

ASCO 2026: CLEARED: Comeback from Long Course ADT with Relugolix and Darolutamide in Hormone-Sensitive Prostate Cancer

|
By Zachary Klaassen Verified, Atish D. Choudhury
| UroToday Verified
(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Atish Choudhury discussing results from CLEARED, a trial assessing a comeback from a long-course androgen deprivation therapy (ADT) with relugolix and darolutamide in hormone-sensitive prostate cancer.
Open in Who Shared Issue with article?
See all 17 licensed articles (27 Total)